Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Dow
McKinsey
Johnson and Johnson
Medtronic

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Urapidil

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Urapidil?

Urapidil is an investigational drug.

There have been 12 clinical trials for Urapidil. The most recent clinical trial was a Phase 1 trial, which was initiated on June 15th 2017.

The most common disease conditions in clinical trials are Hypertension, Stroke, and Hemorrhage. The leading clinical trial sponsors are University Hospital, Strasbourg, France, The George Institute, and National Health and Medical Research Council, Australia.

There are nine hundred and three US patents protecting this investigational drug and seven international patents.

Recent Clinical Trials for Urapidil
TitleSponsorPhase
Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke TrialFirst Affiliated Hospital of Chengdu Medical CollegePhase 3
Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke TrialShanghai East HospitalPhase 3
Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke TrialThe George Institute for Global Health, ChinaPhase 3

See all Urapidil clinical trials

Clinical Trial Summary for Urapidil

Top disease conditions for Urapidil
Top clinical trial sponsors for Urapidil

See all Urapidil clinical trials

US Patents for Urapidil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Urapidil   Start Trial Double-acylated GLP-1 derivatives Novo Nordisk A/S (Bagsvaerd, DK)   Start Trial
Urapidil   Start Trial Double-acylated GLP-1 derivatives Novo Nordisk A/S (Bagsvaerd, DK)   Start Trial
Urapidil   Start Trial Derivatives of GLP-1 like peptides, and uses thereof Novo Nordisk A/S (Bagsvaerd, DK)   Start Trial
Urapidil   Start Trial Ultra-pure agonists of guanylate cyclase C, method of making and using same SYNERGY PHARMACEUTICALS, INC. (New York, NY)   Start Trial
Urapidil   Start Trial Compositions containing polymeric, ionic compounds comprising imidazolium groups BASF SE (Ludwigshafen, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Urapidil

Drugname Country Document Number Estimated Expiration Related US Patent
Urapidil China 104519902 2032-05-08   Start Trial
Urapidil European Patent Office 2846823 2032-05-08   Start Trial
Urapidil Japan 2015517477 2032-05-08   Start Trial
Urapidil Japan 6250034 2032-05-08   Start Trial
Urapidil World Intellectual Property Organization (WIPO) 2013167454 2032-05-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Moodys
Baxter
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.